ReviewFrontiers in oncology2025
Male infertility as a late side effect of oncological treatment of Hodgkin lymphoma in childhood and adolescents and the possible prevention.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the cohort of childhood and adolescent survivors of Hodgkin lymphoma (HL) continues to grow, the possibility of preserving long-term fertility has only amplified in the last decade. With the increasing success of pediatric cancer treatment outcomes, survivors now have the hope of having children of their own. This article critically reviews the relevant methods of gonadal function assessments and treatment therapies. It focuses on the most up-to-date methods of fertility preservation for male Hodgkin lymphoma survivors. Cure rates for HL remain among the best for pediatric cancers, with an overall success of 90-95% attributed to modern treatment. Although efforts to prevent gonadal toxicity continue to be of the utmost importance, ramifications of treatment have prevailed and sperm cryopreservation remains the gold standard method of fertility preservation. Pediatric physicians experience challenges in oncofertility that hinder the provision of high-quality fertility preservation care and patients endure a multitude of physical and psychological consequences that can exacerbate long-term fertility outcomes. Accordingly, fertility maintenance and protection must be considered extremely significant in all young male patients regardless of age, for maximal fertility quality and long-term potential for reproduction. Given the advancements in modern medicine, it is crucial to mitigate the long-term effects of treatments and prioritize fertility preservation options for young males to promote their reproductive autonomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.